ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/bispecific-T-cell-engager-CD20-targeting
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/bispecific-T-cell-engager-CD20-targeting
9
trial(s) found.
NCT07634289
Radonc
Phase 2
Not yet recruiting
Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Phase II
Radio-GLO
Study
bispecific T-cell engager,CD20-targeting
radiotherapy
Diffuse large B-cell lymphoma
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06634589
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies (
BGB-16673-104
)
BTK PROTAC degrader
+ bispecific T-cell engager,CD20-targeting
B-cell lymphoma
NSW
2217 - Kogarah - St George Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06542250
Advanced
Phase 1 / Phase 2
Recruiting
A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With Relapsed or Refractory B-Cell Malignancies (
TITANium
)
bispecific T-cell engager,CD20-targeting
B-cell malignancy
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06414148
Paed
Phase 2
Recruiting
A Phase II Open-Label, Multi-Centre Study of Minimal Residual Disease-Directed Consolidation With Epcoritamab or Epcoritamab-Lenalidomide-Rituximab Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma (
EpLCART
)
anti-CD20 monoclonal antibody
bispecific T-cell engager,CD20-targeting
immunomodulatory imide drug
Diffuse large B-cell lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05991388
Paed
Phase 2 / Phase 3
Recruiting
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (
Glo-BNHL
)
Carboplatin
Dexamethasone
Etoposide
Ifosfamide
Loncastuximab Tesirine
Odronextamab
Rituximab
alkylating agent
anti-CD19 antibody-drug conjugate
anti-CD20 monoclonal antibody
bispecific T-cell engager,CD20-targeting
cancer therapy
cancer therapy,CD19-targeting
cancer therapy,CD20-targeting
cytotoxic chemotherapy
glucocorticoid
immuno-oncology therapy,CD19-targeting
immuno-oncology therapy,CD20-targeting
platinum-based antineoplastic agent
therapeutic modality,bispecific T-cell engager
therapeutic modality,bispecific antibody
topoisomerase inhibitor
+ bispecific T-cell engager,CD20-targeting
Non-Hodgkin's lymphoma
NSW
2145 - Westmead - The Children's Hospital at Westmead
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NCT05533775
Paed
Phase 1 / Phase 2
Recruiting
A Phase I/II, Open-Label, Single-Arm, Two-Part Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination With Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (
iMATRIX-GLO
)
bispecific T-cell engager,CD20-targeting
Non-Hodgkin's lymphoma
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
ACTRN12625000965404
Haem
Phase 3
Not yet recruiting
ALLG CLL10/CLLRT2: A prospective, open-label, randomised, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with Richter Transformation (
CLL-RT2
)
BTK inhibitor
bispecific T-cell engager,CD20-targeting
Cancer
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma,Richter's transformation
ACTRN12625000732482
Haem
Phase 2
Recruiting
CLL12 - An ALLG phase II trial of venetoclax treatment (26 cycles) with 6 cycles or 12 cycles of epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (
AETHER-trial
)
Bcl2 inhibitor
bispecific T-cell engager,CD20-targeting
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
ACTRN12625000387426
Haem
Phase 2
Recruiting
CLL11 - An ALLG phase II trial of Epcoritamab consolidation in high genomic risk and MRD-positive Chronic Lymphocytic Leukaemia (CLL) patients after first-line venetoclax and obinutuzumab (
MOONSHOT
)
Bcl2 inhibitor
anti-CD20 monoclonal antibody
bispecific T-cell engager,CD20-targeting
Chronic lymphocytic leukaemia
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (7)
Not yet recruiting (2)
Recruitment Country and State
WA (6)
QLD (5)
VIC (4)
NSW (3)
NZ (2)
SA (1)
Phase
Phase 1 / Phase 2 (3)
Phase 2 (4)
Phase 2 / Phase 3 (1)
Phase 3 (1)
Trial Type
Paed (3)
Haem (3)
Advanced (2)
Radonc (1)
Cancer Therapy Class
CD20
100%
Bcl2
33%
BTK
22%
cereblon
11%
CD19
11%
IL-6
11%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (3)
6150 - Murdoch - Fiona Stanley Hospital (2)
3004 - Melbourne, Southbank - Alfred Health (2)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (2)
4101 - South Brisbane - Queensland Children's Hospital (2)
6009 - Perth - Perth Children's Hospital (2)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
5042 - Bedford Park - Flinders Medical Centre (1)
2217 - Kogarah - St George Hospital (1)
3168 - Clayton - Monash Medical Centre (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
NZ.0622 - Takapuna - North Shore Hospital (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
2145 - Westmead - The Children's Hospital at Westmead (1)
NZ.1023 - Grafton - Starship Children's Hospital (1)
Cancer Type
Cancer
Haematological malignancy
B-cell malignancy
Lymphoma
Non-Hodgkin's lymphoma
Mature B-cell malignancy
B-cell lymphoma
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Chronic lymphocytic leukaemia
Leukaemia
Lymphoid leukaemia
Diffuse large B-cell lymphoma,Richter's transformation
Small lymphocytic lymphoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy